Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of JNJ-87189401 (PSMA-CD28) + JNJ-78278343 (KLK2-CD3) in Advanced Prostate Cancer
jRCT2031250823Phase 1Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of pasritamig and JNJ-87189401 in prostate adenocarcinoma and prostate neoplasms (PCa) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants With Dose Limiting Toxicity (DLT) in Part 1 and Number of Participants With Adverse Events (AEs) by Severity in Parts 1 and 2. Started May 2026; status: recruiting.
02
Drugs
pasritamigJNJ-87189401
03
Conditions
prostate adenocarcinomaprostate neoplasms (PCa)
Beyond the preview
Go deeper on jRCT2031250823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250823.